Source: Global Research.ca
In 2012, Cuba patented the first therapeutic vaccine in the world against advanced lung cancer, called CIMAVAX-EGF. In January 2013, the island announced the second cancer vaccine, known as Racotumomab. Clinical tests carried out in 86 nations revealed…they do reduce the tumors thus improving the quality and expectancy of life of the patients.
The Havana-based Molecular Immunology Center is the creator of these vaccines. The center had already developed the Meningitis-B Vaccine in 1985, followed by such as the Hepatitis-B and the Dengue vaccines. The Cuban agenda against cancer is also joined by Labiofam pharmaceutical enterprise, which develops homeopathic medications against the disease such as VIDATOX, made from the venom of blue scorpion, native of Cuba.
At present, Cuba exports these products to 26 countries and participates in joint ventures in China, Canada and Spain. This breaks the…the largely voiced stereotype that advanced pharmaceutics is only developed in the developed countries.
And although Cuba obtains economic revenues from the sales of its products, its research philosophy diametrically opposes the market policies of the big pharmaceutical industry.
Cuba attains higher health indicators than the United States using up to twenty times less resources, according to an article in Science Magazine by Paul Drain and Michele Barry, two scientists at the Standford University in California. It happens that there are no commercial or market pressures or profits on the Cuban model, while there is a successful educative strategy for the population as to prevention…
In Cuba, medicines are distributed to the people firstly, through the hospital network free of charge and through a system of drugstores that sell them at highly subsidized prices. The Cuban pharmaceutical industry hardly uses money for publicity, which in the case of multi-national corporations this activity surpasses the budgets dedicated to doing research.
It is important to note that the US economic blockade of Cuba hinders the marketing of Cuban pharmaceuticals in the United States, thus affecting the US people. For instance, a total of 80 thousand diabetic people who undergo toe amputation every year in the United States every year cannot access the Cuban vaccine known as Heberprot-P, which precisely avoids such amputations.
Chemistry Nobel Prize winner Peter Agre recently said that Cuba is a magnificent example of how knowledge and scientific research can be integrated. The general director of UNESCO, Irina Bokova, said that she was impressed at the scientific achievements of Cuba and expressed her organization’s willingness to promote them around the world.
So then, the question to be asked here is: Will UNESCO be able to count on the crucial collaboration by the mainstream media to promote the Cuban achievements?